On October 14, local time, artificial intelligence pharmaceutical company Iambic Therapeutics announced the initial public offering price of 16 US dollars per share, issuing 9.375 million shares, and is expected to raise 150 million US dollars. The underwriters also received the option to purchase up to 1,40625 million additional shares within 30 days. The company's stock is expected to be listed and traded on the NASDAQ Global Select Market on October 15. The stock code is “IAM”, and the issuance is expected to be completed on October 16. J.P. Morgan Chase, Jefferies, Bank of America Securities, and Citigroup serve as joint bookkeeping managers. Iambic uses artificial intelligence and automated chemical and biological experimental technology to advance drug research and development, and its drug candidate IAM1363 has entered the clinical stage. Nvidia was involved in supporting the company's financing.

On October 14, local time, artificial intelligence pharmaceutical company Iambic Therapeutics announced the initial public offering price of 16 US dollars per share, issuing 9.375 million shares, and is expected to raise 150 million US dollars. The underwriters also received the option to purchase up to 1,40625 million additional shares within 30 days. The company's stock is expected to be listed and traded on the NASDAQ Global Select Market on October 15. The stock code is “IAM”, and the issuance is expected to be completed on October 16. J.P. Morgan Chase, Jefferies, Bank of America Securities, and Citigroup serve as joint bookkeeping managers. Iambic uses artificial intelligence and automated chemical and biological experimental technology to advance drug research and development, and its drug candidate IAM1363 has entered the clinical stage. Nvidia was involved in supporting the company's financing.